Pre-DLI or Pro-DLI in Relapsed/Refractory Myeloid Neoplasms After HSCT

Exclusion Criteria

• •Early mortality or relapse within 30 days post-transplantation.
• •Active graft-versus-host disease (GVHD) not under control between 30 and 60 days post-transplantation.
• •Presence of severe or uncontrolled infections.
• •Presence of significant organ dysfunction, defined as:
• •Hepatic dysfunction: Known severe cirrhosis, portal hypertension, or active liver disease; or laboratory-confirmed alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \> 3.0 × the upper limit of normal (ULN) and/or total bilirubin (TBIL) \> 1.5 × ULN.
• •Renal dysfunction: Estimated glomerular filtration rate (eGFR) \< 60 mL/min/1.73m² (calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation) or serum creatinine \> 1.5 × ULN; or requirement for regular hemodialysis or peritoneal dialysis.
• •Cardiac dysfunction: New York Heart Association (NYHA) functional class III or IV; unstable angina, acute myocardial infarction, coronary artery bypass grafting (CABG), or percutaneous coronary intervention (PCI) within 6 months prior to enrollment; left ventricular ejection fraction (LVEF) \< 50% (confirmed by echocardiography or other Doppler examination); clinically significant, uncontrolled arrhythmia.
• •Respiratory dysfunction: Chronic obstructive pulmonary disease (COPD) or other pulmonary disease requiring long-term oxygen therapy; resting oxygen saturation (SpO₂) \< 92% on room air.
• •Participation in another investigational drug trial within the 3 months prior to enrollment.
• •Any other condition deemed by the investigator to make the patient unsuitable for the study.